What one share of Taysha Gene Therapies holds
We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.
Taysha Gene Therapies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.41 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.37 |
| Cash and investments | $1.40 |
| Debt | $0.15 |
| Book value | $1.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$3.40 | $0.00 | −$1.74 | — | — |
| 2021 | — | −$4.64 | $0.41 | −$3.52 | — | — |
| 2022 | $0.06 | −$3.78 | $0.47 | −$2.48 | — | $0.01 |
| 2023 | $0.13 | −$0.96 | $0.03 | −$0.66 | — | $0.40 |
| 2024 | $0.03 | −$0.36 | $0.00 | −$0.33 | — | $0.35 |
| 2025 | $0.03 | −$0.34 | $0.00 | −$0.29 | — | $0.87 |
Common questions about Taysha Gene Therapies
How much does one share of Taysha Gene Therapies earn?
Over the last 12 months, Taysha Gene Therapies lost $0.41 for each share on $0.02 of sales.
Does Taysha Gene Therapies pay a dividend?
Taysha Gene Therapies didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Taysha Gene Therapies’s book value per share?
Taysha Gene Therapies’s book value is $1.19 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Taysha Gene Therapies have?
Each share of Taysha Gene Therapies has $1.40 of cash and investments and $0.15 of debt, as of June 30, 2026.
What is Taysha Gene Therapies’s free cash flow per share?
−$0.37 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Taysha Gene Therapies bought back shares?
Taysha Gene Therapies’s share count rose about 1710% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.